$PARAGONREIT(SK6U.SG)$
what's your take on the cash offer?

新的一年里我还没有开始投资，在2022年里我还是会继续努力买Tesla的，然后长期持有。希望它能让我提早退休

$Johnson & Johnson(JNJ.US)$ $SINOPHARM(01099.HK)$ COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna(MRNA.US)$ , $ASTRAZENECA PLC(AZNCF.US)$ and $Pfizer(PFE.US)$ and partner $BioNTech(BNTX.US)$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline(GSK.US)$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

$Microsoft(MSFT.US)$ Morgan Stanley analyst Keith Weiss pointed out in a research report that in the first half of 2021, the revenue from data platform solutions accounted for approximately 12% of Microsoft's (MSFT.US) total revenue, which was higher than About 10% in the same period in 2017.
Weiss said: "Investors often overlook Microsoft's absolute leadership in this area."
Weiss pointed out that considering Microsoft's leading position in data platforms and related businesses, including large data platforms such as Azure database, Azure analytics, SQL Server database and Power BI, the analyst believes that the strong database demand environment will have strong performance for Microsoft in 2022 Growth plays a vital role.
Weiss had previously rated Microsoft as "overweight" and maintained the target price at $364. As of yesterday's close, Microsoft's stock price fell 3.26% to $328.340.
Article excerpted from the US Stock Research Agency

$UP Fintech(TIGR.US)$ the best Christmas present ever… pony tail wagging

$SIA(C6L.SG)$ get ready buying mode

$SIA(C6L.SG)$I received it in June until now, 4.85 dollars. It has been raised several times without being sold. It feels foolish to get it, and it's a waste of profit...

$Tesla(TSLA.US)$ Tesla recovery is no joke